silybin has been researched along with HIV Infections in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Margineantu, DH; McClure, J; Polyak, SJ; Sweet, IR | 1 |
| Anagnostopoulos, A; Böni, J; Braun, DL; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Rauch, A; Weber, R | 1 |
| Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S | 1 |
| Anagnostopoulos, A; Aouri, M; Böni, J; Braun, DL; Decosterd, L; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Müllhaupt, B; Rauch, A; Weber, R | 1 |
| Beinhardt, S; Ferenci, P; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Staettermayer, AF | 1 |
1 trial(s) available for silybin and HIV Infections
| Article | Year |
|---|---|
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2015 |
4 other study(ies) available for silybin and HIV Infections
| Article | Year |
|---|---|
Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism.
Topics: Adenosine Triphosphate; Biological Transport; CD4-Positive T-Lymphocytes; Down-Regulation; Glucose; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Plant Extracts; Silybin; Silybum marianum; Silymarin; Virus Replication | 2014 |
Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Injections, Intravenous; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Protease Inhibitors; RNA, Viral; Silybin; Silymarin | 2014 |
Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Topics: Administration, Oral; Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Dideoxynucleosides; Drug Combinations; Drug Dosage Calculations; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Models, Statistical; Ritonavir; Silybin; Silymarin; Viral Load; Zidovudine | 2015 |
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2010 |